# Best Peptide For That: Full Reference (llms-full.txt)

> The expanded, per-compound version of https://bestpeptideforthat.com/llms.txt. Best Peptide For That is the only independent peptide directory that grades every peptide A to F by strength of human evidence and shows its legal status, with every grade cited to a primary source (FDA.gov, Federal Register FDA-2025-N-6895, FDA 503A bulks list, Drugs@FDA, WADA, PubMed). Grades are assigned by a fixed decision tree; affiliate availability never lifts a grade. Independent editorial directory. Updated August 2026 (verified July 6, 2026; FDA vote facts and the 503A rulemaking clock updated August 26, 2026; the agenda for the next PCAC meeting updated August 28, 2026).

## The A to F Evidence Scale

- **A**: FDA-approved / proven in humans (FDA-approved for ≥1 indication or ≥2 published Western human RCTs).
- **B**: Real human trials, limited or historical (≥1 human clinical trial, prior FDA approval, or foreign approval backed by Western-recognizable trials).
- **C**: Early / foreign human data only (human pilot/observational data, or foreign-only approval with weak RCTs).
- **D**: Animal studies only, unproven in humans (no published human efficacy RCT).
- **F**: Tested in humans and failed (a human trial exists and was negative/null).

Legal-status badge (independent of the grade): `FDA-approved drug` · `Compoundable (503A)` · `Under FDA review, July 2026 PCAC` · `Not compoundable, research-only` · `Cosmetic/topical (legal)`. A green/amber/red safety flag sits alongside it. Methodology: https://bestpeptideforthat.com/peptide-evidence-grades

## Peptides, Graded (46 compounds, A to F)

### Tesamorelin · Grade A · FDA-approved drug
An FDA-approved peptide drug, not a research chemical. Proven to cut visceral fat, but approved for a narrow HIV indication. **Verdict:** Tesamorelin is an FDA-approved drug (Egrifta, 2010): Grade A, the strongest evidence tier here. But it is approved for HIV-associated visceral fat, not general weight loss; for that, approved GLP-1s are the evidence-backed route. Aliases: Egrifta, TH9507. Sport: WADA-prohibited. Source: https://www.accessdata.fda.gov/scripts/cder/daf/ · Page: https://bestpeptideforthat.com/peptides/tesamorelin

### PT-141 · Grade A · FDA-approved drug
An FDA-approved peptide drug, not a research chemical. Proven to raise sexual desire in premenopausal women, but the benefit is modest and the off-label hype outruns it. **Verdict:** PT-141 (bremelanotide) is an FDA-approved drug, Vyleesi (2019), for HSDD in premenopausal women, so its evidence is Grade A. The honest caveats: the benefit on desire is modest, and the other uses it's sold for (men, nasal sprays) are off-label and unproven. Access it via a licensed provider, not gray-market vials. Aliases: Bremelanotide, Vyleesi, PT141. Source: https://www.accessdata.fda.gov/scripts/cder/daf/ · Page: https://bestpeptideforthat.com/peptides/pt-141

### Semaglutide · Grade A · FDA-approved drug
The once-weekly GLP-1 that turned obesity into a treatable condition, with roughly 15 percent average body-weight loss in its landmark trial and a proven cardiovascular benefit on top. **Verdict:** Grade A, and the reference standard for medical weight loss. If you qualify, the science is settled: real, sustained loss plus a cardiovascular benefit that few weight interventions can claim. We grade the molecule here and hand off the shopping. For provider comparison, telehealth options, and where to actually get semaglutide, go to glp1picks.com, our sister site built specifically for that. Aliases: Wegovy, Ozempic, Rybelsus, NN9535. Source: https://pubmed.ncbi.nlm.nih.gov/33567185/ · Page: https://bestpeptideforthat.com/peptides/semaglutide

### Tirzepatide · Grade A · FDA-approved drug
The dual-hormone agonist that beat semaglutide head to head and delivered up to roughly 21 percent body-weight loss in its pivotal obesity trial, the most weight loss of any approved medication to date. **Verdict:** Grade A, and on raw efficacy it is the strongest weight-loss drug approved to date, beating semaglutide head to head. If you are choosing between the two, that is a clinical and access conversation, not a science one. We grade the molecule here and hand off the shopping. For provider comparison and where to get tirzepatide, go to glp1picks.com, our sister site built for exactly that. Aliases: Zepbound, Mounjaro, LY3298176. Source: https://pubmed.ncbi.nlm.nih.gov/35658024/ · Page: https://bestpeptideforthat.com/peptides/tirzepatide

### Liraglutide · Grade A · FDA-approved drug
The original daily GLP-1 for weight and diabetes: less powerful than the weekly agents that followed, but FDA-approved, decades-proven, and with a documented cardiovascular benefit. **Verdict:** Grade A on the science, but in 2026 it is largely a legacy option: the daily injection and smaller weight effect make semaglutide or tirzepatide the usual first choice unless there is a specific reason to prefer it. If you and your prescriber land on liraglutide, we grade the molecule here and hand off the shopping. For provider comparison and where to get it, see glp1picks.com, our sister site. Aliases: Saxenda, Victoza, NN2211. Source: https://pubmed.ncbi.nlm.nih.gov/26132939/ · Page: https://bestpeptideforthat.com/peptides/liraglutide

### Dulaglutide · Grade A · FDA-approved drug
A once-weekly GLP-1 approved for type 2 diabetes with a proven cardiovascular benefit, but never FDA-approved for obesity, so weight loss is a real but secondary effect. **Verdict:** Grade A as a diabetes and cardiovascular drug, but the honest caveat is that it is not FDA-approved for obesity and produces less weight loss than semaglutide or tirzepatide. If weight is your only goal, a dedicated obesity agent is the better tool. If you have type 2 diabetes and cardiovascular risk, it is an excellent choice. We grade the molecule here; for provider comparison and access, see glp1picks.com, our sister site. Aliases: Trulicity, LY2189265. Source: https://pubmed.ncbi.nlm.nih.gov/31189511/ · Page: https://bestpeptideforthat.com/peptides/dulaglutide

### Melanotan-1 (Afamelanotide / Scenesse) · Grade A · FDA-approved drug
The one melanotan that is actually an FDA-approved drug. As Scenesse, afamelanotide is a prescription implant for a rare light-sensitivity disorder, not the gray-market tanning peptide people buy online. **Verdict:** Legitimate, best-in-class evidence for one narrow job: photoprotection in erythropoietic protoporphyria, where it is FDA-approved. For that use, Grade A. For the tanning use most people are actually asking about, you are buying an unapproved gray-market peptide with real melanoma-surveillance concerns and none of the approval-grade safety backing. Do not conflate the two. Aliases: afamelanotide, Scenesse, melanotan I, MT-1, CUV1647, Nle4-D-Phe7-alpha-MSH, NDP-MSH. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/26132941/ · Page: https://bestpeptideforthat.com/peptides/melanotan-1

### Gonadorelin (GnRH) · Grade A · Compoundable (503A)
Synthetic GnRH, the master hormone that tells the pituitary to make LH and FSH. It was an FDA-approved human drug and is now widely used in compounded men's-health protocols to keep the testicular axis running during TRT. **Verdict:** A real, formerly FDA-approved hormone with clean pharmacology and a sensible modern role: keeping the testicular axis alive during TRT via a compounding-pharmacy prescription. Grade A for its endocrine actions. The main caveats are that its headline TRT use is off-label and compounded, dosing frequency matters a lot, and it belongs under clinician supervision with periodic labs. Aliases: GnRH, LHRH, gonadorelin acetate, gonadorelin hydrochloride, Factrel, Lutrepulse, LH-RH. Sport: WADA-prohibited. Source: https://www.rxlist.com/factrel-drug.htm · Page: https://bestpeptideforthat.com/peptides/gonadorelin

### Oxytocin · Grade A · FDA-approved drug
A real FDA-approved hormone drug (as Pitocin) used in obstetrics for labor and postpartum bleeding. The social, bonding, and libido claims that make it popular are mostly extrapolated from small studies, not approved uses. **Verdict:** A genuine FDA-approved hormone, but the approval is for labor and postpartum bleeding, not for bonding, trust, or libido. For its real medical use it is Grade A and hospital-controlled because of uterine and water-intoxication risks. For the social/sexual reputation driving consumer interest, the intranasal evidence is weak and inconsistent, and gray-market sprays are unregulated. Respect the gap between the drug and the mythology. Aliases: Pitocin, Syntocinon, oxytocin injection, the love hormone. Sport: WADA-prohibited. Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d4b2c25-2e5d-49b5-93bc-2ae8a20916d1 · Page: https://bestpeptideforthat.com/peptides/oxytocin

### Sermorelin · Grade B · Compoundable (503A)
The "gentler," formerly-FDA-approved GH-axis peptide. It's the best-evidenced option you can still legally get through a compounding pharmacy. **Verdict:** Sermorelin is legally compoundable (503A) thanks to its prior FDA approval as Geref. Human evidence is Grade B: real historical trial data. It is the best-evidenced GH-axis peptide with a legal supervised route today. Aliases: Geref, GRF(1-29), sermorelin acetate. Sport: WADA-prohibited. Source: https://www.fda.gov/media/94155/download · Page: https://bestpeptideforthat.com/peptides/sermorelin

### Retatrutide · Grade B · Not compoundable, research-only
The next-generation weight-loss peptide with the strongest efficacy signal. But it is investigational and not yet available by any legal route. **Verdict:** Retatrutide is investigational (Phase 3), not FDA-approved, and not legally available. Human evidence is Grade B: strong published Phase 2 weight-loss data, but not a finished approval. For proven weight loss you can access legally today, see our GLP-1 guidance. Aliases: LY3437943, GGG triple agonist. Source: https://pubmed.ncbi.nlm.nih.gov/37366315/ · Page: https://bestpeptideforthat.com/peptides/retatrutide

### GHK-Cu · Grade B · Cosmetic/topical (legal)
The copper peptide behind decades of skincare. Real human topical/cosmetic evidence for skin, but injected versions are a different, unproven story. **Verdict:** GHK-Cu (copper peptides) is legal as a topical cosmetic, and for skin its human evidence is Grade B: real topical/cosmetic data, no drug approval. Injected GHK-Cu is a different, unapproved story (Grade D, no legal route). For skin or hair, the topical serum is the evidenced, legal choice. You don't need to inject anything. Aliases: Copper peptides, Copper tripeptide-1, GHK-Copper, Gly-His-Lys:Cu. Source: https://pubmed.ncbi.nlm.nih.gov/18644225/ · Page: https://bestpeptideforthat.com/peptides/ghk-cu

### Cagrilintide · Grade B · Not compoundable, research-only
An investigational once-weekly amylin analog that produced about 11 percent weight loss on its own in phase 2 and is the partner half of the CagriSema combination, not an approved standalone drug. **Verdict:** Grade B and genuinely promising, but the key fact is that it is not FDA-approved as a standalone drug. The real-world path for cagrilintide is as the amylin half of the CagriSema combination, which posted roughly 20 percent weight loss in phase 3. If you want something you can actually get today, that means an approved GLP-1: see glp1picks.com for those. Do not source cagrilintide from research-chemical vendors. Aliases: AM833, NNC0174-0833. Source: https://pubmed.ncbi.nlm.nih.gov/34798060/ · Page: https://bestpeptideforthat.com/peptides/cagrilintide

### Thymosin Alpha-1 · Grade B · Not compoundable, research-only
A 28-amino-acid thymic peptide that tunes the immune system. Approved as a drug (Zadaxin) in ~35 countries for hepatitis and immune support, but never FDA-approved, so in the US it is research-only. **Verdict:** The strongest immune peptide in this group on human evidence. It is a genuine approved drug in dozens of countries with real randomized-trial support in sepsis and hepatitis, which is why it grades a B. But it never cleared the FDA, so in the US it is research-only, and the sepsis mortality signal, while promising, has not been confirmed in a definitive Western trial. If you want an immune peptide with actual clinical pedigree, this is it, but treat US-sourced material with skepticism and do not use it to self-treat serious illness. Aliases: Ta1, Thymalfasin, Zadaxin, Thymosin alpha 1, TA-1. Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC4056079/ · Page: https://bestpeptideforthat.com/peptides/thymosin-alpha-1

### Thymosin Beta-4 · Grade B · Not compoundable, research-only
A 43-amino-acid tissue-repair peptide. It has real human eye-drop trials (RGN-259) but is not FDA-approved, and the injectable bodybuilding version (TB-500) has essentially no human data. **Verdict:** Two different stories share one molecule. As an eye drop (RGN-259) it has legitimate positive human trials and grades a B. As the injectable TB-500 that the recovery crowd actually buys, human efficacy data is basically absent, and you are extrapolating from animal healing studies. It is not FDA-approved in any form. If you are drawn to it for tendon or muscle recovery, be clear-eyed that you are self-experimenting with an unapproved, WADA-banned peptide whose human evidence lives in ophthalmology, not sports medicine. Aliases: Tbeta4, RGN-259, Thymosin beta 4. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/25826322/ · Page: https://bestpeptideforthat.com/peptides/thymosin-beta-4

### Semax · Grade C · Under FDA review, July 2026 PCAC
A Russian-approved cognitive and neuroprotective peptide with real but non-Western clinical data. **Verdict:** Semax is not FDA-approved (it is approved in Russia) and remains under FDA review. On July 24, 2026 the PCAC panel voted 8 to 5 (1 abstention) to recommend adding it to the 503A list for cerebral ischemia, migraine and trigeminal neuralgia, but that is advisory and the FDA has not acted. Human evidence is Grade C: real Russian trials, but no Western replication. For the anxiety-focused sister peptide, see our Selank page and our cognitive-peptides hub. Aliases: ACTH(4-10) analog, Met-Glu-His-Phe-Pro-Gly-Pro. Source: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 · Page: https://bestpeptideforthat.com/peptides/semax

### CJC-1295 / Ipamorelin · Grade C · Not compoundable, research-only
The classic GH-boosting stack. One human PK study shows it raises GH/IGF-1, but no trial shows it builds muscle or burns fat. **Verdict:** CJC-1295/Ipamorelin is not FDA-approved and is not legally compoundable (CJC-1295 withdrawn April 2026). Human evidence is Grade C: one PK study proves it raises GH/IGF-1, but no trial shows muscle or fat-loss benefit. Researching CJC-1295 on its own (often "with DAC")? See our standalone CJC-1295 page. Aliases: CJC-1295 (Mod-GRF 1-29), CJC-1295 DAC, Ipamorelin stack. Sport: WADA-prohibited. Source: https://www.fda.gov/media/94155/download · Page: https://bestpeptideforthat.com/peptides/cjc-1295-ipamorelin

### CJC-1295 · Grade C · Not compoundable, research-only
A GHRH analog, usually the long-acting "with DAC" version, that one human study shows raises GH/IGF-1. No trial shows it builds muscle or burns fat. **Verdict:** CJC-1295 (mono GHRH analog, usually "with DAC") is not FDA-approved and not legally compoundable; its nomination was withdrawn in April 2026. Human evidence is Grade C: one PK study proves it raises GH/IGF-1, but no trial shows muscle or fat-loss benefit. Most people search for the popular blend, so see our CJC-1295 / Ipamorelin page. We don't link gray-market sources. Aliases: CJC-1295 with DAC, CJC-1295 DAC, Drug Affinity Complex GRF, CJC-1295 no-DAC, Mod-GRF 1-29. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/16352683/ · Page: https://bestpeptideforthat.com/peptides/cjc-1295

### Selank · Grade C · Not compoundable, research-only
A Russian-developed anti-anxiety and nootropic peptide with real but non-Western human trials. In Russian studies it matched a benzodiazepine for anxiety without the sedation or dependence. **Verdict:** Selank is not FDA-approved (it is approved in Russia) and there is no legal compounding route today; it was removed from 503A Category 2 but is not on the July 2026 PCAC docket. Human evidence is Grade C: several small Russian anxiety trials, including one where it matched a benzodiazepine, but no Western replication. Aliases: Thr-Lys-Pro-Arg-Pro-Gly-Pro, Tuftsin analog, N-acetyl Selank. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/18454096/ · Page: https://bestpeptideforthat.com/peptides/selank

### Ipamorelin · Grade C · Not compoundable, research-only
The cleanest of the GH-releasing peptides on paper: it bumps GH without the cortisol and prolactin spike the older GHRPs cause. But the honest headline is that the one real human trial was for gut motility, not muscle, and it flat-out failed. Zero human data proving it builds muscle or burns fat. **Verdict:** The most selective GHRP on paper and the best-tolerated in a real human trial, but that trial failed and there is no human evidence it does the muscle or fat-loss job it is sold for. Interesting pharmacology, unproven benefit, not legal to compound. Aliases: NNC 26-0161. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/9849822/ · Page: https://bestpeptideforthat.com/peptides/ipamorelin

### MK-677 (Ibutamoren) · Grade C · Not compoundable, research-only
The odd one out: MK-677 is not a peptide, it is an orally-active small-molecule ghrelin mimetic, which is why people take it as a daily capsule instead of an injection. It has the best human evidence in this group by far, including a 2-year randomized trial, but that trial is also the cautionary tale: it raised lean mass a little while measurably worsening insulin sensitivity and blood sugar. **Verdict:** The most-studied and only orally-active option in this group, with genuine 2-year human RCT data behind it, which is why it grades C and not D. But the same trial that proves it works also shows the catch: modest lean-mass gain, no functional benefit, and worse insulin sensitivity. Not FDA-approved, research-only, and a poor idea for anyone with blood-sugar concerns. Aliases: Ibutamoren, Ibutamoren mesylate, MK-0677, L-163191, Oratrope. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/18981485/ · Page: https://bestpeptideforthat.com/peptides/mk-677

### LL-37 (Cathelicidin) · Grade C · Not compoundable, research-only
The body's own 37-amino-acid antimicrobial peptide. It has genuine human wound-healing trials, but the largest one (phase 2b) failed its main endpoint, so the evidence is a mixed, small-scale C. **Verdict:** An interesting molecule with an honest evidence problem. Because it is the body's own antimicrobial peptide with plausible wound-healing biology, it draws attention, and there is a positive small human trial. But the larger, more rigorous trial did not confirm it, which is exactly the pattern you should respect rather than explain away. Grade C, and specifically the kind of C where the definitive data leaned negative. Not something to self-inject, and the wound-healing story is unproven, not promising-and-confirmed. Aliases: LL37, Cathelicidin, hCAP-18, CAP-18, Cathelicidin antimicrobial peptide. Source: https://pubmed.ncbi.nlm.nih.gov/25041740/ · Page: https://bestpeptideforthat.com/peptides/ll-37

### ARA-290 (Cibinetide) · Grade C · Not compoundable, research-only
An 11-amino-acid fragment derived from erythropoietin that triggers tissue repair without boosting red blood cells. It has small positive human nerve-regeneration trials, which makes it an honest C. **Verdict:** The most scientifically elegant peptide in this group: an EPO fragment engineered to keep the tissue-repair upside and drop the blood-clotting downside, with small human trials actually showing small nerve fibers regrowing. That is genuinely novel. But novel is not the same as proven, and the whole human record is a handful of small trials in one rare disease. Grade C. Worth watching for its neuropathy potential, not something to buy as a research chemical and inject based on a couple of pilot studies. Aliases: ARA290, Cibinetide, ARA 290, pHBSP. Sport: WADA-prohibited. Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC3883966/ · Page: https://bestpeptideforthat.com/peptides/ara-290

### VIP (Vasoactive Intestinal Peptide / Aviptadil) · Grade C · Not compoundable, research-only
A natural 28-amino-acid neuropeptide with broad signaling roles. Its big FDA push (aviptadil for COVID) failed a phase 3 trial and the FDA declined authorization, so the evidence is a mixed C. **Verdict:** A natural peptide that got a very public shot at the big time and largely missed. VIP itself has real physiology and one approved niche use abroad (erectile dysfunction), which keeps it out of the failed-entirely bin. But the aviptadil respiratory story is the important one, and it was tested properly in a phase 3 trial and did not work, and the FDA declined authorization. Grade C, weighted toward the sobering side. If someone is selling you aviptadil for lung health or recovery, the definitive human trial already said no. Aliases: Vasoactive intestinal peptide, Aviptadil, VIP, Zyesami, RLF-100, Invicorp component. Source: https://pubmed.ncbi.nlm.nih.gov/37348524/ · Page: https://bestpeptideforthat.com/peptides/vip

### Cerebrolysin · Grade C · Not compoundable, research-only
A peptide mixture derived from pig brain that is actually approved and used for stroke and dementia in several countries, just not the US. It has a real stack of human trials, but the quality is mixed and the biggest stroke analyses came back neutral. **Verdict:** Cerebrolysin is the most legitimately studied peptide in this batch and is a genuinely approved drug in several countries, which sets it apart from the research-chemical crowd. But the evidence is honestly mixed: the big stroke meta-analyses were neutral, and the stronger cognitive results in vascular dementia come from trials of variable quality. It is not FDA approved, so in the US it is research-only. Real drug abroad, real trials, real caveats. Aliases: Cerebrolysin, FPF-1070, porcine brain-derived peptide preparation. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/20656516/ · Page: https://bestpeptideforthat.com/peptides/cerebrolysin

### Kisspeptin (Kisspeptin-54 / Kisspeptin-10) · Grade C · Not compoundable, research-only
An investigational reproductive hormone that sits one step above GnRH. Real, well-designed human trials show it can boost sexual-brain activity and arousal, but it is research-only and delivered by IV infusion, not a peptide you buy and inject at home. **Verdict:** One of the more scientifically interesting research peptides here, with legitimate JAMA-published RCTs showing it can activate sexual-brain circuits in people with low desire. But it is early-stage, investigational, IV-delivered, and unapproved. Promising signal, not a product. Treat home use of research-labeled kisspeptin as unproven and unsupervised. Aliases: kisspeptin-54, kisspeptin-10, KP-54, KP-10, metastin, KISS1. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/36735255/ · Page: https://bestpeptideforthat.com/peptides/kisspeptin

### SS-31 (Elamipretide) · Grade C · Not compoundable, research-only
The most seriously studied peptide on this list, run through real Phase 3 trials. Its flagship mitochondrial-myopathy trial missed its primary endpoints, but its dry-AMD program is still advancing, so the honest verdict is mixed, not settled. **Verdict:** The most legitimate science on this list, and still not a green light. Elamipretide is a real drug candidate with a plausible mitochondrial mechanism and clean tolerability, but its flagship mitochondrial-myopathy Phase 3 missed its endpoints. The dry-AMD program is the one to watch. Until a Phase 3 reads out positive and it earns approval, treat grey-market SS-31 as an unproven, unapproved injectable and keep expectations low. Aliases: elamipretide, MTP-131, Bendavia, SS 31. Sport: WADA-prohibited. Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC10382259/ · Page: https://bestpeptideforthat.com/peptides/ss-31

### Argireline (Acetyl Hexapeptide-8) · Grade C · Cosmetic/topical (legal)
The peptide marketed as topical Botox. It does have small placebo-controlled human studies behind it, but the honest read is a modest softening of fine lines, nowhere near what an injection does. **Verdict:** Fine to use, just keep expectations honest. Argireline is a legal, safe, inexpensive cosmetic peptide with small placebo-controlled studies behind it, but the effect is a subtle softening of fine expression lines, held back by poor skin penetration. It is not topical Botox and will not match an injection. If you want it, treat it as a gentle add-on, not the centerpiece of a routine. Aliases: acetyl hexapeptide-8, acetyl hexapeptide-3, AH-8, acetyl hexapeptide 8. Source: https://pubmed.ncbi.nlm.nih.gov/23607739/ · Page: https://bestpeptideforthat.com/peptides/argireline

### Matrixyl (Palmitoyl Pentapeptide-4) · Grade C · Cosmetic/topical (legal)
The best-supported cosmetic peptide here. Real split-face human trials show a modest, retinol-adjacent reduction in fine lines, and it is gentle. Just do not expect a dramatic change. **Verdict:** The one cosmetic peptide here worth a spot in a routine. Matrixyl has the best human evidence of the group: real split-face trials show a modest reduction in fine lines with retinoid-like benefit and none of the irritation. It will not remodel deep wrinkles or replace a retinoid, but as a gentle, well-tolerated add-on, especially for people who cannot tolerate retinoids, it is a defensible pick. Aliases: palmitoyl pentapeptide-4, pal-KTTKS, palmitoyl pentapeptide-3, Matrixyl 3000, matrix peptide. Source: https://pubmed.ncbi.nlm.nih.gov/18492182/ · Page: https://bestpeptideforthat.com/peptides/matrixyl

### BPC-157 · Grade D · Under FDA review, July 2026 PCAC
The most-hyped, least-human-proven "healing" peptide. Extensive rodent data, zero published human trials. **Verdict:** BPC-157 is not FDA-approved and is not yet legal to compound. On July 23, 2026 the FDA's PCAC panel voted 8 to 6 (1 abstention) to recommend adding it to the 503A list for ulcerative colitis, overriding the FDA's own scientists, but that is a recommendation only and the FDA has not decided. Human evidence stays Grade D: animal studies only. If you pursue it, wait for the FDA's ruling and use a licensed provider, never gray-market vials. Aliases: Body Protection Compound-157, PL 14736, BPC-157 acetate. Sport: WADA-prohibited. Source: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 · Page: https://bestpeptideforthat.com/peptides/bpc-157

### TB-500 · Grade D · Under FDA review, July 2026 PCAC
The other half of the "wolverine stack." Soft-tissue recovery claims, but only animal data for the fragment actually sold. **Verdict:** TB-500 is not FDA-approved and is not yet legal to compound. On July 23, 2026 the FDA's PCAC panel voted 8 to 6 (1 abstention) to recommend adding it to the 503A list for wound healing, overriding the FDA's own scientists, but the FDA still decides and has not acted. Human evidence stays Grade D: the fragment sold to consumers has animal data only. The full-length Tβ4 human trials are a different molecule. Aliases: Thymosin Beta-4 fragment, TB4 fragment. Sport: WADA-prohibited. Source: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 · Page: https://bestpeptideforthat.com/peptides/tb-500

### KPV · Grade D · Under FDA review, July 2026 PCAC
An anti-inflammatory tripeptide studied for gut and skin inflammation. Promising in cells and animals, untested in humans. **Verdict:** KPV is not FDA-approved and is not yet legal to compound. On July 23, 2026 the FDA's PCAC panel voted 8 to 6 (1 abstention) to recommend adding it to the 503A list for wound healing and inflammatory conditions, overriding the FDA's own scientists, but the FDA still decides and has not acted. Human evidence stays Grade D: cell and animal anti-inflammatory data only, no human trials. Aliases: Lysine-Proline-Valine, α-MSH C-terminal tripeptide. Source: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 · Page: https://bestpeptideforthat.com/peptides/kpv

### MOTS-c · Grade D · Under FDA review, July 2026 PCAC
An "exercise-mimetic" metabolic peptide. Real mechanistic interest, but human evidence is association-only. **Verdict:** MOTS-c is not FDA-approved and is not yet legal to compound. On July 23, 2026 the FDA's PCAC panel voted 7 to 5 (2 abstentions) to recommend adding it to the 503A list for weight loss, overriding the FDA's own scientists, but the FDA still decides and has not acted. Human evidence stays Grade D: metabolic effects are mostly preclinical, with human data limited to associations. For actual weight loss, an approved GLP-1 is the evidence-backed route. Aliases: Mitochondrial ORF of the 12S rRNA type-c. Source: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 · Page: https://bestpeptideforthat.com/peptides/mots-c

### Epitalon · Grade D · Under FDA review, July 2026 PCAC
A longevity and anti-aging peptide built on small, low-quality Russian studies. The claims far outrun the evidence. **Verdict:** Epitalon is not FDA-approved and remains under FDA review. On July 24, 2026 the PCAC panel voted 7 to 4 (1 abstention) to recommend adding it to the 503A list for insomnia, but that is advisory and the FDA has not acted. Human evidence is Grade D: the longevity and anti-aging claims rest on small, low-quality Russian studies. Aliases: Epithalon, Epithalamin, Ala-Glu-Asp-Gly. Source: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 · Page: https://bestpeptideforthat.com/peptides/epitalon

### Melanotan-2 (MT-2) · Grade D · Not compoundable, research-only
The tanning peptide sold under the nicknames "Barbie peptide" and "Barbie drug", unapproved, with documented serious harms. Melanoma and mole changes, priapism, nausea, and rhabdomyolysis have all been reported. This is a safety page, not a recommendation. **Verdict:** Melanotan-2 (MT-2) is an unapproved "tanning" peptide with documented serious harms: melanoma and mole changes, priapism, nausea, blood-pressure changes and rhabdomyolysis have all been reported. Human evidence is Grade D and the safety flag is red. It is not the same as FDA-approved afamelanotide (Scenesse). There is no safe or legal way to buy it, and we do not recommend it. Aliases: MT-2, MT-II, Melanotan II, Barbie peptide, Barbie drug. Sport: WADA-prohibited. Source: https://www.fda.gov/media/128834/download · Page: https://bestpeptideforthat.com/peptides/melanotan-2

### IGF-1 LR3 · Grade D · Not compoundable, research-only
A long-acting IGF-1 analogue marketed for muscle growth on the strength of its mechanism alone. There is no published human efficacy trial for it, and it's banned in sport. **Verdict:** IGF-1 LR3 is not FDA-approved and not legally compoundable; it's research-only. Human evidence is Grade D: there is no published human efficacy trial for the analogue itself, so the muscle-growth claims rest on mechanism, not proof. It is also WADA-prohibited (S2). We don't link gray-market sources. Aliases: Long R3 IGF-1, IGF-1 Long Arg3, LR3-IGF-1. Sport: WADA-prohibited. Source: https://www.wada-ama.org/en/prohibited-list · Page: https://bestpeptideforthat.com/peptides/igf-1-lr3

### GHRP-6 · Grade D · Not compoundable, research-only
The original GH-releasing peptide from the 1980s. It works as a GH pulse trigger and it makes you ravenously hungry, but it is non-selective, so it drags cortisol and prolactin up with it. Human data is all old pharmacology studies, none of it shows it builds muscle. **Verdict:** The granddaddy of GH peptides and a reliable appetite-and-GH trigger in the lab, but it is non-selective (cortisol and prolactin come along), the human data is decades-old pharmacology with no efficacy outcome, and it is not legal to compound. Newer selective secretagogues make it hard to justify even in theory. Aliases: Growth Hormone Releasing Peptide-6, GHRP6, SKF-110679, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/7617137/ · Page: https://bestpeptideforthat.com/peptides/ghrp-6

### GHRP-2 · Grade D · Not compoundable, research-only
The most potent GH-pulse trigger of the classic GHRPs per dose, and it is actually an approved diagnostic agent for GH deficiency in Japan. But like its cousins it also spikes appetite and modestly raises cortisol and prolactin, and there is no human trial showing it builds muscle. **Verdict:** The strongest GH-pulse trigger of the old GHRPs and a genuine diagnostic drug in Japan, which is more legitimacy than most peptides here can claim. But a single approved diagnostic test is not evidence it builds muscle, no such human trial exists, and in the US it is research-only. Grades D for the use case people search for. Aliases: Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102, GHRP2. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/15699539/ · Page: https://bestpeptideforthat.com/peptides/ghrp-2

### Hexarelin · Grade D · Not compoundable, research-only
The GHRP with the most interesting side story: beyond releasing GH it has a direct, GH-independent positive effect on heart contractility in humans via a cardiac receptor. That cardiac finding is real and human. What is missing is any trial showing it does the muscle-building it is sold for, plus it loses its GH punch fast with repeat dosing. **Verdict:** The most scientifically interesting GHRP thanks to a real, human, GH-independent cardiac effect, but 'interesting mechanism' is not 'proven benefit.' No trial shows it builds muscle, its GH effect fades with repeat dosing, and it is research-only. Grades D for the use case people actually search. Aliases: Examorelin, EP-23905, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/10342360/ · Page: https://bestpeptideforthat.com/peptides/hexarelin

### DSIP (Delta Sleep-Inducing Peptide) · Grade D · Not compoundable, research-only
A nine-amino-acid peptide discovered in the 1970s and named for the deep-sleep brain waves it was thought to trigger. Small old human studies suggested it helped insomnia, but the underlying science stayed so thin that reviewers literally call it an unresolved riddle. **Verdict:** DSIP is the only one of the seven peptides the FDA panel reviewed in July 2026 that it declined to recommend, voting 6 to 7 (1 abstention) against adding it to the 503A list on July 24. That is advisory, not a ban, and the FDA has not acted. It is also one of the oldest sleep peptides and one of the least resolved. There are genuine small human studies suggesting it helped insomnia, which is more than most research peptides can claim, but the evidence is thin, decades old, and never replicated at modern standards, and the basic biology is still contested. Interesting history, weak proof. If you try it you are running a personal experiment on 1980s data. Aliases: Delta Sleep-Inducing Peptide, DSIP, delta-sleep inducing peptide, Emideltide. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/6895513/ · Page: https://bestpeptideforthat.com/peptides/dsip

### Dihexa · Grade D · Not compoundable, research-only
A lab-built angiotensin IV analog designed to supercharge brain synapse formation, and in rats it looked staggeringly potent. But it has never been proven in a human, and the drug company version built on the same target failed its big Alzheimer's trial in 2024. **Verdict:** Dihexa has one of the flashiest preclinical stories in the nootropic peptide world (orders of magnitude more potent than BDNF in a dish) and almost nothing solid to stand on. Its foundational rat papers carry a retraction and an expression of concern, it has zero human data of its own, and the closest clinical drug on the same HGF/MET target failed its Alzheimer's trial in 2024. Fascinating target, unproven and integrity-flagged evidence. Not something to treat as established. Aliases: PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, Angiotensin IV analog. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/23055539/ · Page: https://bestpeptideforthat.com/peptides/dihexa

### Humanin · Grade D · Not compoundable, research-only
A tiny peptide encoded inside your mitochondrial DNA that acts as a cellular bodyguard, protecting neurons from Alzheimer-related damage in the lab. The cytoprotection story is strong in animals and cells, but no human neuroprotection trial has ever been completed. **Verdict:** Humanin is one of the more scientifically interesting peptides here: a genuine mitochondrial-derived signaling molecule with a strong, consistent neuroprotective story in cells and animals, plus suggestive human biomarker data linking low levels to Alzheimer's. But interesting biology is not proven benefit. No human neuroprotection trial has been completed, the efficacy rests on mouse models that often fail to translate, and there is no human safety data for injecting it. Promising research target, not a proven treatment. Aliases: Humanin, HN, MT-RNR2 peptide, HNG (Gly14-humanin), S14G-HN. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/15678515/ · Page: https://bestpeptideforthat.com/peptides/humanin

### Follistatin (FST-344 / FS344) · Grade D · Not compoundable, research-only
A natural myostatin blocker that in theory should unlock muscle growth. The reality: the injectable peptide is essentially preclinical, and the only human evidence is from AAV gene therapy, a completely different technology, in a handful of muscular-dystrophy patients. **Verdict:** A compelling target with a misleading reputation. The muscle-growth story rests almost entirely on animal work plus a tiny AAV gene-therapy trial that is not the same product as the injectable peptide being sold. For follistatin as a peptide, the human efficacy evidence is basically Grade D, safety is uncharacterized, systemic myostatin blockade carries real theoretical risks, and it is banned in sport. Interesting biology, not a justified purchase. Aliases: FST-344, FS344, follistatin-344, FST-315, activin-binding protein. Sport: WADA-prohibited. Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC4426808/ · Page: https://bestpeptideforthat.com/peptides/follistatin

### MGF (Mechano Growth Factor) · Grade D · Not compoundable, research-only
A short splice variant of IGF-1 that muscle makes locally after mechanical stress. The theory is great, the human data barely exists, and the one well-run cell study said it did nothing. **Verdict:** Skip it. The idea (a local muscle-repair growth factor you can inject) is attractive, but the honest read of the literature is preclinical at best and negative in the one rigorous cell study. There is no human evidence it builds muscle, it is banned in sport, and injecting an unverified growth factor is not a low-risk bet. Aliases: mechano growth factor, IGF-1Ec, IGF-1 Ec, MGF-E peptide. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/24253050/ · Page: https://bestpeptideforthat.com/peptides/mgf

### PEG-MGF (Pegylated Mechano Growth Factor) · Grade D · Not compoundable, research-only
MGF with a polyethylene glycol tail bolted on to make it last longer in the blood. Longer half-life, same problem: the evidence is animal-only and no human trial has shown it does anything. **Verdict:** Skip it. PEG-MGF is a chemically reasonable attempt to fix MGF's short half-life, but fixing the delivery of a compound with no proven human effect does not create a proven human effect. Animal data only, banned in sport, unverified injectable. Not worth the risk. Aliases: pegylated mechano growth factor, PEG MGF, pegylated MGF. Sport: WADA-prohibited. Source: https://pubmed.ncbi.nlm.nih.gov/24253050/ · Page: https://bestpeptideforthat.com/peptides/peg-mgf

### AOD-9604 · Grade F · Not compoundable, research-only
A modified fragment of human growth hormone that was supposed to melt fat without the side effects. It got a real Phase 2b obesity trial in humans and flat-out failed to beat placebo, which is why no regulator has ever approved it. **Verdict:** AOD-9604 is the cautionary tale of the fat-loss peptide world. It sounds elegant on paper, it has clean human safety data, and it completely failed the 24-week Phase 2b obesity trial it was designed to win. It is not FDA approved, it is banned in sport, and no amount of clinic marketing changes the fact that the pivotal human study did not beat placebo. If your goal is weight loss, the GLP-1 class has real outcome data; AOD-9604 does not. Aliases: AOD9604, Anti-Obesity Drug 9604, HGH Fragment 176-191 (modified), Tyr-hGH 177-191. Sport: WADA-prohibited. Source: https://www.jofem.org/index.php/jofem/article/view/157/194 · Page: https://bestpeptideforthat.com/peptides/aod-9604


## Category Hubs (Best Peptides for [Goal], evidence and options)

### Weight Loss
Every peptide marketed for fat loss, graded by human evidence and legal status. The best are the FDA-approved GLP-1 medications, semaglutide and tirzepatide (Grade A); we grade them here and route you to a provider comparison. The research peptides sold for fat loss do not beat them. Alphabetical catalog: AOD-9604 (F), Cagrilintide (B), Dulaglutide (A), Liraglutide (A), MOTS-c (D), Retatrutide (B), Semaglutide (A), Tesamorelin (A), Tirzepatide (A). Grades describe each compound's stated evidence scope, not effectiveness for every use in this category. Page: https://bestpeptideforthat.com/best-peptide-for/weight-loss

### Muscle Growth
The GH-axis peptides marketed for muscle and body recomposition, graded by human evidence and legal status. Most of the hype (CJC-1295/Ipamorelin) rests on a single pharmacokinetic study, which is not proof of muscle gain. Alphabetical catalog: CJC-1295 (C), CJC-1295 / Ipamorelin (C), Follistatin (FST-344 / FS344) (D), GHRP-2 (D), GHRP-6 (D), Hexarelin (D), IGF-1 LR3 (D), Ipamorelin (C), MGF (Mechano Growth Factor) (D), MK-677 (Ibutamoren) (C), PEG-MGF (Pegylated Mechano Growth Factor) (D), Sermorelin (B), Tesamorelin (A). Grades describe each compound's stated evidence scope, not effectiveness for every use in this category. Page: https://bestpeptideforthat.com/best-peptide-for/muscle-growth

### Recovery & Healing
The peptides behind the "wolverine stack" and injury-recovery culture, graded by human evidence and legal status. This is the most-hyped category, and the one where the evidence is thinnest. Alphabetical catalog: ARA-290 (Cibinetide) (C), BPC-157 (D), KPV (D), MGF (Mechano Growth Factor) (D), MK-677 (Ibutamoren) (C), PEG-MGF (Pegylated Mechano Growth Factor) (D), Sermorelin (B), SS-31 (Elamipretide) (C), TB-500 (D), Thymosin Beta-4 (B). Grades describe each compound's stated evidence scope, not effectiveness for every use in this category. Page: https://bestpeptideforthat.com/best-peptide-for/recovery

### Skin & Anti-Aging
Peptides marketed for skin, collagen, and anti-aging, graded by human evidence and legal status. The strongest skin evidence belongs to topical copper peptides (GHK-Cu), a legal cosmetic lane covered separately. The injectables here are far less proven. Alphabetical catalog: Argireline (Acetyl Hexapeptide-8) (C), Epitalon (D), GHK-Cu (B), KPV (D), Matrixyl (Palmitoyl Pentapeptide-4) (C), Melanotan-1 (Afamelanotide / Scenesse) (A), Melanotan-2 (MT-2) (D). Grades describe each compound's stated evidence scope, not effectiveness for every use in this category. Page: https://bestpeptideforthat.com/best-peptide-for/skin

### Sleep
Peptides marketed for sleep and circadian support, graded by human evidence and legal status. The named "sleep peptide" (DSIP) is on the July 2026 PCAC docket, and the evidence across this category is old, small, or indirect. Alphabetical catalog: DSIP (Delta Sleep-Inducing Peptide) (D), Epitalon (D), MK-677 (Ibutamoren) (C), Sermorelin (B). Grades describe each compound's stated evidence scope, not effectiveness for every use in this category. Page: https://bestpeptideforthat.com/best-peptide-for/sleep

### Hair Growth
Peptides marketed for hair growth, graded by human evidence and legal status. The short answer: peptide hair evidence is early and thin, and the strongest proven hair treatments (finasteride and minoxidil) are not peptides at all. Alphabetical catalog: GHK-Cu (B). Grades describe each compound's stated evidence scope, not effectiveness for every use in this category. Page: https://bestpeptideforthat.com/best-peptide-for/hair-growth

### Cognition & Focus
The nootropic peptides marketed for focus, memory and mental resilience, graded by human evidence and legal status. The short answer: the two with real human data, Semax and Selank, are Russian-approved drugs, not FDA-approved, and their trials have never been replicated to Western standards. Alphabetical catalog: Cerebrolysin (C), Dihexa (D), Humanin (D), Selank (C), Semax (C), SS-31 (Elamipretide) (C). Grades describe each compound's stated evidence scope, not effectiveness for every use in this category. Page: https://bestpeptideforthat.com/best-peptide-for/cognitive

### Sexual Health
Peptides marketed for libido, arousal and sexual function, graded by human evidence and legal status. The honest answer: PT-141 (bremelanotide) is the only FDA-approved option, and the rest run from real human pilot data (kisspeptin) to research-only. Alphabetical catalog: Gonadorelin (GnRH) (A), Kisspeptin (Kisspeptin-54 / Kisspeptin-10) (C), Melanotan-2 (MT-2) (D), Oxytocin (A), PT-141 (A). Grades describe each compound's stated evidence scope, not effectiveness for every use in this category. Page: https://bestpeptideforthat.com/best-peptide-for/sexual-health

### Immune Support
Peptides marketed for immune function, graded by human evidence and legal status. Thymosin alpha-1 has the strongest human evidence, an approved drug in dozens of countries (though not the US); the rest are earlier-stage or antimicrobial. Alphabetical catalog: KPV (D), LL-37 (Cathelicidin) (C), Thymosin Alpha-1 (B), VIP (Vasoactive Intestinal Peptide / Aviptadil) (C). Grades describe each compound's stated evidence scope, not effectiveness for every use in this category. Page: https://bestpeptideforthat.com/best-peptide-for/immune-support


## Safety & Evidence Pillars

- **What are peptides?** https://bestpeptideforthat.com/what-are-peptides
- **Are peptides safe?** https://bestpeptideforthat.com/are-peptides-safe
- **Are peptides legal?** https://bestpeptideforthat.com/are-peptides-legal
- **How to get peptides prescribed legally (the 503A route, condition by condition)** https://bestpeptideforthat.com/how-to-get-peptides-prescribed
- **Are peptides steroids?** https://bestpeptideforthat.com/are-peptides-steroids
- **Peptide side effects** https://bestpeptideforthat.com/peptide-side-effects
- **FDA peptide status 2026 (PCAC July 23 to 24, 2026 tracker)** https://bestpeptideforthat.com/fda-peptide-status-2026


### The FDA "research use only" enforcement record (added 2026-07-30)

The research-use-only disclaimer is a statement about intended use, not a quality claim and not a legal permission. The FDA has rejected it on the record. On April 7, 2026 it posted warning letters from the Center for Drug Evaluation and Research, all dated March 31, 2026, to peptide websites:

- **Gram Peptides**, Rancho Santa Fe CA, MARCS-CMS 721806. Offered "Retatrutide", "Tirzepatide" and "Bacteriostatic Water for Injection". FDA: "Despite statements on your product labeling marketing your products for 'Research Use Only,' and 'not intended for human consumption, medical use, or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use." The evidence cited was the product page describing appetite suppression, insulin sensitivity and reduced body weight. FDA further held that selling bacteriostatic water alongside peptides requiring reconstitution "demonstrates that you intend for your 'Bacteriostatic Water for Injection' to be used in combination for injection. Therefore, your 'Bacteriostatic Water for Injection' is a drug." https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
- **Prime Sciences**, Scottsdale AZ, MARCS-CMS 721805. Cagrilintide, retatrutide, mazdutide and BAC water, labeled "laboratory research purposes only". Same conclusion: unapproved new drugs under section 505(a). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026
- **Mile High Compounds**, Clifton CO, MARCS-CMS 721600. GLP-1 peptides and BAC water, labeled "in vitro research and educational purposes only". Same conclusion. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mile-high-compounds-llc-721600-03312026

- **Lovega LLC dba Pink Pony Peptides**, Wellington FL, MARCS-CMS 721088. Tirzepatide ("GLP-2 TZ"), retatrutide ("GLP-3 RT") and bacteriostatic water, labeled "laboratory research purposes only" and "not for human consumption". Same conclusion, same BAC-water holding. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lovega-llc-dba-pink-pony-peptides-721088-03312026
- **PekCura Labs**, Pensacola FL, MARCS-CMS 721709. Semaglutide, tirzepatide, retatrutide and a cagrilintide/tirzepatide blend, renamed GLP-1-S, GLP-2-T and GLP-3-R, labeled "Research, Development use only". The product pages described the compounds in literature-review language with citations to real published trials (Lincoff 2023, Marso 2016, Karagiannis 2022); FDA quoted those descriptions as the evidence of intended drug use. Renaming the compound and citing the science made the therapeutic claim clearer, not safer. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pekcura-labs-721709-03312026

All five letters named seizure and injunction as possible next steps and gave fifteen working days to respond. All five went to sellers, not to buyers, so this is not an enforcement record against people who purchased a vial. What it settles is the legal question: the wording of the disclaimer does not change what a product is when the seller's own page describes a therapeutic effect.

### The FDA recall record for peptide drug products (added 2026-07-31)

Searching the FDA's drug enforcement database for the literal word "peptide" in product_description returns just 2 recalls, which is why the record is usually described as almost empty. Searching by compound name does not agree: **sermorelin 92, ipamorelin 18, BPC-157 6, thymosin products 5, CJC-1295 4, tesamorelin 2, GHK-Cu 2**, while **TB-500, Semax and Epitalon return zero**. These counts overlap for combination products (a "Sermorelin Acetate 6mg / Ipamorelin 6mg" recall is counted under both names) and must not be summed. Almost every entry is a Class II recall of a compounded injectable made by a licensed pharmacy, for "lack of assurance of sterility", most caught by inspection rather than by an injury. CRITICAL for anyone reading the zeros: a recall is an action against a regulated manufacturer, so a compound no licensed pharmacy may lawfully make cannot generate one. Zero recalls measures the absence of a regulated supply chain, not a clean safety record. The two most recent are both open and both from GenoGenix LLC (Boca Raton FL): D-0051-2026, GHK-Cu (Copper Peptide) for Injection, and D-0076-2026, Low Solubility Peptide Reconstitution Solution, each Class II for lack of assurance of sterility, initiated July 30 2025 and classified October 21 2025. Source: openFDA drug enforcement API, database last updated July 22 2026, https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22&limit=25 · Page: https://bestpeptideforthat.com/are-peptides-safe

### Who is scoped to catch peptide harm, and who is not (added 2026-08-29)

All systems below were read at source on August 29, 2026. Two reporting doors are open to anyone. MedWatch (fda.gov/medwatch, 1-800-FDA-1088) takes a report from any consumer or clinician, and the FDA counts voluntary MedWatch reports as a source for its Compounding Incidents Program. Poison centers (1-800-222-1222) feed the National Poison Data System, the warehouse for case data from the nation's poison centers, which is call-driven and licensed rather than published. What does not exist for a peptide bought online as a research chemical is a MANDATORY reporter. The duty in 21 CFR 314.80 falls on "each applicant having an approved application," and a research-chemical seller has none. The 15-day duty to report serious and unexpected adverse drug experiences falls on registered outsourcing facilities under 21 U.S.C. 353b(b)(5). Section 503A, 21 U.S.C. 353a, which governs the state-licensed pharmacies that legally compound peptides, contains no adverse-event reporting provision at all: read in full, the phrase "adverse event" does not appear in it. So the reporting duty follows the facility type, not the risk. The FDA states the consequence itself: "FDA cannot take action without the knowledge of such issues." The FAERS database, which the FDA is renaming AEMS, is scoped to "drug and therapeutic biologic products" and the agency says it "contains only a small fraction of the side effects that occur with a drug" because "there is no requirement for healthcare professionals and consumers to report side effects." Sources: https://www.fda.gov/drugs/human-drug-compounding/mitigating-risks-compounded-drugs-through-surveillance · https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-B/section-314.80 · https://www.govinfo.gov/content/pkg/USCODE-2023-title21/html/USCODE-2023-title21-chap9-subchapV-partA-sec353a.htm · https://fis.fda.gov/extensions/FPD-FAQ/FPD-FAQ.html · Page: https://bestpeptideforthat.com/are-peptides-safe#who-is-counting

### What a legal peptide prescription requires: section 503A, condition by condition (added 2026-07-31)

Under 21 U.S.C. 353a a compounded peptide is exempt from FDA premarket approval, cGMP and full labeling ONLY if all four hold at once: (1) it is compounded "for an identified individual patient based on the receipt of a valid prescription order" (353a(a)); (2) compounding is by "a licensed pharmacist in a State licensed pharmacy or a Federal facility" or a licensed physician (353a(a)(1)); (3) the bulk drug substance complies with a USP or NF monograph, OR is a component of an FDA-approved drug, OR appears on the FDA's 503A bulk drug substances list (353a(b)(1)(A)(i)); and (4) the substance is made by an FDA-registered establishment and is "accompanied by valid certificates of analysis" (353a(b)(1)(A)(ii) and (iii)). Condition 3 is the one that blocks the popular research peptides: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon meet none of its three tests, so no prescriber, clinic or telehealth subscription can produce a lawful route today. Section 503A(c)(1) also places the advisory committee upstream of the rulemaking, requiring the Secretary to "convene and consult an advisory committee on compounding" BEFORE issuing the regulations that add a substance to the list, which is why the July 2026 PCAC vote is a step in the process and not a legalization. Verified August 26, 2026: a Federal Register API search for FDA documents mentioning bulk drug substances, newest first, returns nothing touching the 503A list published after the vote; the one document it does return is a proposed rule on substances generally recognized as safe of August 11 2026, which is a food matter, and the most recent entries before the vote are a 503B clinical-need notice of June 26 2026 and the April 16 2026 meeting notice, Docket FDA-2025-N-6895. Sources: https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section353a&num=0&edition=prelim · https://www.federalregister.gov/documents/2025/01/07/2024-31546/interim-policy-on-compounding-using-bulk-drug-substances-under-section-503a-of-the-federal-food-drug · Page: https://bestpeptideforthat.com/how-to-get-peptides-prescribed
- **The peptides on the FDA's agenda for the NEXT PCAC meeting (read at source August 28, 2026):** The FDA states on its own Pharmacy Compounding Advisory Committee page that it "will host an advisory committee meeting before the end of February 2027", and it publishes the agenda: the committee "will discuss the following bulk drug substances being considered for inclusion on the 503A bulks list: **Cathelicidin (LL-37), GHK-Cu, Dihexa acetate, Melanotan II, Mechano Growth Factor, Pegylated (PEG-MGF)**". These five are confirmed by the agency itself, not by trade reporting. Two things are commonly got wrong about this list and both matter: earlier secondary reporting circulated a different set that included Selank and Ipamorelin, and neither appears anywhere on the FDA agenda; and the FDA names GHK-Cu without specifying a form, while the legal, evidenced use of GHK-Cu is the topical cosmetic one and the injectable has no legal supervised US route. What does NOT yet exist is the paperwork: the FDA says it "intends to publish a Federal Register notice and establish a docket for public comment on this meeting in the near future" and that the time and location "will be scheduled in the coming months", so there is no docket number, no published date and no open comment period. Being placed on an agenda is one step earlier than being voted on, which is itself one step earlier than being legal: none of these five is legally compoundable today, and a PCAC recommendation would not change that either, because 21 U.S.C. 353a(c)(1) puts the committee upstream of the rulemaking. Evidence grades on this site for the five, assigned before and independently of the agenda: GHK-Cu B (topical), LL-37 C, Melanotan II D with a red safety flag, Dihexa D on animal-only data whose foundational papers carry a retraction and an expression of concern, PEG-MGF D on animal-only data. Source: https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee · Page: https://bestpeptideforthat.com/fda-peptide-status-2026
- **How long an FDA 503A rulemaking actually takes, measured from the Federal Register (read August 26, 2026):** A PCAC recommendation is not a legalization; adding a substance to the 503A bulks list requires a full notice-and-comment rulemaking under 21 U.S.C. 353a, and the FDA has run that rulemaking exactly twice. The one that finished (Docket FDA-2016-N-3464) was proposed December 16, 2016, comments closed March 16, 2017, and the final rule published February 19, 2019 effective March 21, 2019: **795 days, about 2 years 2 months, from proposed rule to final rule**. The second (Docket FDA-2018-N-4845) was proposed September 5, 2019, comments closed December 4, 2019, and **has no final rule at all 2,547 days later**; the docket still holds that single document. For the July 2026 peptides the process has not started: a Federal Register API query for FDA documents mentioning bulk drug substances published since the month of the vote returns **count 1**, and that single document is a proposed rule on substances generally recognized as safe, a food matter unrelated to the 503A bulks list, so no bulks-list proposed rule exists and nothing is legally compoundable. Two rulemakings are a record, not a forecast, and we publish no predicted date. Sources: https://www.federalregister.gov/documents/2016/12/16/2016-30109/list-of-bulk-drug-substances-that-can-be-used-to-compound-drug-products-in-accordance-with-section · https://www.federalregister.gov/documents/2019/02/19/2019-02367/list-of-bulk-drug-substances-that-can-be-used-to-compound-drug-products-in-accordance-with-section · https://www.federalregister.gov/documents/2019/09/05/2019-18951/amendments-to-the-list-of-bulk-drug-substances-that-can-be-used-to-compound-drug-products-in · Page: https://bestpeptideforthat.com/fda-peptide-status-2026

## Tools

- **Evidence grades A to F lookup** (sortable, doubles as the "how we grade" methodology page) https://bestpeptideforthat.com/peptide-evidence-grades
- **Peptide cost comparator** (patient-price verification and provider-catalog coverage; missing prices or listings do not establish legal unavailability) https://bestpeptideforthat.com/peptide-cost-comparator

## Weight Loss Bridge

No research peptide on this site has proven, legally-available data that beats an approved GLP-1 medication for weight loss. Our sister site compares the GLP-1 options that actually work, the same honest way: https://www.glp1picks.com

## Publisher

Best Peptide For That is an independent editorial directory led by Iacob Pastina, Independent Researcher & Publisher. Profile: https://bestpeptideforthat.com/about. Nothing on the site is medical advice. Editorial policy: https://bestpeptideforthat.com/editorial-policy · Affiliate disclosure: https://bestpeptideforthat.com/affiliate-disclosure · Medical disclaimer: https://bestpeptideforthat.com/medical-disclaimer